Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

Anna G. Turkina, MD, PhD, Olga Vinogradova, PhD, Alexandra Vorontsova, PhD, Ekaterina Chelysheva, PhD, Olga Lazareva, PhD, Galina Gusarova, PhD, Elena Aseeva, PhD, Nina Khoroshko, MD, PhD

Blood (2011) 118 (21): 1683.

https://doi.org/10.1182/blood.V118.21.1683.1683

Published: 2011

Journal Articles

The Role of Imatinib Plasma Level in the Achievment of Complete Cytogenetic Response (CCyR) in Chronic Myeloid Leukemia (CML) Therapy

Sergey Kutsev, MD, PhD, Oxana Oxenjuk, MD, Sergey Mordanov, MD, Yuri Shatokhin, MD, PhD, Tatiana Pospelova, MD, PhD, Nina Khoroshko, MD, PhD, Anna Turkina, MD, PhD

Blood (2011) 118 (21): 3789.

https://doi.org/10.1182/blood.V118.21.3789.3789

Published: 2011

Journal Articles

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Anna G. Turkina, MD, PhD, Sergey Kulikov, Kudrat Abdulkadirov, Sergey Kutsev, MD, PhD, Anatoly Golenkov, MD, Valentina Ivanova, Tatiana Pospelova, MD, PhD, Tatiana Konstantinova, Olga Lazareva, PhD, Nina Khoroshko, MD, PhD

Blood (2011) 118 (21): 4447.

https://doi.org/10.1182/blood.V118.21.4447.4447

Published: 2011

Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman

Blood (2009) 113 (25): 6322–6329.

https://doi.org/10.1182/blood-2008-11-186817

Published: 2009

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, PhD, Pedro Dorlhiac-Llacer, Ricardo Pasquini, Nina Khoroshko, John F. DiPersio, MD, PhD, Martin C Müller, MD, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman, MD

Blood (2008) 112 (11): 3224.

https://doi.org/10.1182/blood.V112.11.3224.3224

Published: 2008

Journal Articles

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, Neil Shah

Blood (2007) 109 (12): 5143–5150.

https://doi.org/10.1182/blood-2006-11-056028

Published: 2007

NARROW

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

The Role of Imatinib Plasma Level in the Achievment of Complete Cytogenetic Response (CCyR) in Chronic Myeloid Leukemia (CML) Therapy

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Email alerts

ASH Publications

American Society of Hematology

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

The Role of Imatinib Plasma Level in the Achievment of Complete Cytogenetic Response (CCyR) in Chronic Myeloid Leukemia (CML) Therapy

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only